FDA 483 OBSERVATION · #294 OF 1,923 MOST-CITED

Component identity verification

FDA cited this observation 98 times across 95 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Drugs98
BY FISCAL YEAR
FY20266
FY202511
FY202415
FY202313
FY20225
FY20212
FY20204
FY20198
FY201810
FY201716
FY20168

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 6× the rate of the average FDA-cited firm (46.3% vs 7.8%), across 95 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Westwood Laboratories, LLC. · Azusa, California · Drugs · 2026-03-26

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Dr. J Skinclinic, Inc · Cerritos, California · Drugs · 2026-03-23

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Blaine Labs Inc · Santa Fe Springs, California · Drugs · 2025-12-22

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

J. Strickland and Co · Olive Branch, Mississippi · Drugs · 2025-11-20

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Keystone Industries · Gibbstown, New Jersey · Drugs · 2025-11-07

Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

Weckerle Cosmetics USA, INC · Torrance, California · Drugs · 2025-10-31

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →